Patients With Cancer
Conditions
Brief summary
This is a retrospective study that included 60 cancer patients who underwent autologous NK cell and CD8 T cell therapy between January 2016 and December 2021
Detailed description
The dysfunction and reduced proliferation of peripheral immune cells including CD8 T and NK cells have been observed in both aging and cancer patients, thereby challenging the immune cell therapy in these subjects. Therefore, we evaluated the growth of these lymphocytes in elderly patients with several types of cancer and the correlation of peripheral blood (PB) indexes to the expansions. This is a retrospective study that included 60 cancer patients who underwent autologous NK cell and CD8 T cell therapy between January 2016 and December 2021. By optimizing the antiviral and tumor surveillance ability of both NK cells and CTLs through serial steps from isolation and expansion, followed by re-infusion of these activated cells back to the patient body, AIET has become a promising, cutting-edge method in detecting and eliminating cancer cells. The study aimed to evaluate the safety and effectiveness of 60 cancer patientsreceiving AIET.
Interventions
COMBINATION_PRODUCTAutologous immune enhancement therapy (AIET) for cancer patients
Autologous NK cell and CD8 T cell therapy for cancer patients
Sponsors
Vinmec Research Institute of Stem Cell and Gene Technology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged 18 - 75 * Patients have been diagnosed with cancer. * Patients signed the written informed consent form.
Exclusion criteria
* Severe health conditions such as serious infection, autoimmune diseases, or using any anti-rejection drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse events and serious adverse events (AEs or SAEs) | up to the 36-month period following treatment | the number of AEs or SAEs during and after Autologous Immune Enhancement Therapy (AIET) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in health-related quality of life of patients | up to the 36-month period following treatment | Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 |
| Survival time of patients in this study | up to the 36-month period following treatment | Survival time was defined as from the date of diagnosis until death or the end of this study |
| Changes in Symptoms of patients using MD Anderson Symptoms Inventory Gastrointestinal Cancer Module (MDASI ) | up to the 36-month period following treatment | MDASI contains a 24-item questionnaire. MDASI-GI symptom items are assessed on a numeric scale ranging from 0 or not present to 10 or as bad as you can imagine. The MDASI is a concise, internally stable, and sensitive tool for measuring multiple-symptom severity and symptom interference with function in patients with cancer. |
Countries
Vietnam
Outcome results
None listed